Meeting
2023 ASCO Annual Meeting
TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.
Authors
Yelena Y. Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Y. Janjigian , Ana Oaknin , Joshua Michael Lang , Kristen Keon Ciombor , Isabelle Laure Ray-Coquard , Amit M. Oza , Kan Yonemori , Rui-Hua Xu , Jimmy Zhao , Srikanth Gajavelli , Justyna Filant , Tina Hovey , Funda Meric-Bernstam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05489211
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3153)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3153
Abstract #
TPS3153
Poster Bd #
351a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).
First Author: Peter Schmid
Poster
2022 ASCO Annual Meeting
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.
First Author: Benjamin Philip Levy
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results.
First Author: Anwaar Saeed
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
First Author: Eileen Mary O'Reilly